Glaukos Corporation $GKOS Holdings Decreased by Intech Investment Management LLC

Intech Investment Management LLC trimmed its position in Glaukos Corporation (NYSE:GKOS) by 12.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 43,615 shares of the medical instruments supplier’s stock after selling 6,480 shares during the quarter. Intech Investment Management LLC owned approximately 0.08% of Glaukos worth $4,925,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in GKOS. UBS Group AG increased its holdings in shares of Glaukos by 316.0% in the 4th quarter. UBS Group AG now owns 873,942 shares of the medical instruments supplier’s stock valued at $98,677,000 after acquiring an additional 663,849 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Glaukos by 38.5% in the 3rd quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock valued at $141,365,000 after acquiring an additional 481,620 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of Glaukos by 23.3% in the 3rd quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier’s stock valued at $183,796,000 after acquiring an additional 425,790 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Glaukos by 10.4% in the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock valued at $292,004,000 after acquiring an additional 336,266 shares during the last quarter. Finally, Capital International Investors increased its holdings in shares of Glaukos by 107.5% in the 3rd quarter. Capital International Investors now owns 511,510 shares of the medical instruments supplier’s stock valued at $41,714,000 after acquiring an additional 264,971 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Trading Down 0.3%

NYSE:GKOS opened at $103.08 on Monday. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $148.11. The firm has a market capitalization of $6.05 billion, a P/E ratio of -31.43 and a beta of 0.83. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. The business has a 50 day simple moving average of $121.31 and a 200 day simple moving average of $114.45.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The business had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. During the same quarter in the previous year, the firm posted ($0.22) EPS. The business’s revenue for the quarter was up 41.2% compared to the same quarter last year. Equities research analysts predict that Glaukos Corporation will post -0.57 EPS for the current year.

Insiders Place Their Bets

In other Glaukos news, CFO Alex R. Thurman sold 10,000 shares of the business’s stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $140.00, for a total transaction of $1,400,000.00. Following the completion of the transaction, the chief financial officer owned 43,681 shares in the company, valued at approximately $6,115,340. The trade was a 18.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 19,573 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.54, for a total value of $2,809,508.42. Following the transaction, the chief operating officer owned 73,419 shares of the company’s stock, valued at $10,538,563.26. This trade represents a 21.05% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 45,930 shares of company stock worth $6,321,363. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on GKOS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. Citigroup boosted their price objective on Glaukos from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Stifel Nicolaus set a $170.00 price objective on Glaukos in a research report on Thursday, April 30th. Wall Street Zen lowered Glaukos from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. boosted their price objective on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $146.17.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.